Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111666 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101
A Phase 1 study, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT04111666: Completed Phase 1 study, sponsored by Alector.
NCT04111666 is a Phase 1 study that has completed, run by Alector. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04111666, a Phase 1 study, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
Primary Outcome
Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.
Interventions
- OTHER Placebo
- BIOLOGICAL AL101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-12-14 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 1 |
What the finished NCT04111666 record still lists
NCT04111666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04111666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04111666 about?
NCT04111666 is a clinical study titled "A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101". A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
What is the current status of trial NCT04111666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2019-12-14. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT04111666?
The interventions under investigation include: Placebo (OTHER), AL101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04111666?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04111666's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI